London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Jefferies raises Indivior price target to 2,390 (2,165) pence - 'buy' (12 March 2024)
More good news!
RICHMOND, Va. - Indivior PLC (LSE/Nasdaq: LON:INDV) has announced the results of a pharmacodynamic study indicating that its drug OPVEE® can quickly reverse opioid-induced respiratory depression, a major cause of death in opioid overdoses. The study, comparing intranasal nalmefene (OPVEE) with intranasal naloxone, was published in the Journal of Clinical Pharmacology.
The study met its primary endpoint by showing that OPVEE reversed respiratory depression within five minutes of administration, while naloxone took 20 minutes to achieve a similar effect. Minute ventilation, a measure of breathing, reached approximately 95% of the pre-opioid baseline within five minutes after OPVEE was administered.
In the study, 69 healthy volunteers experienced a reduction in minute ventilation after being administered remifentanil, a synthetic opioid. They were then treated with either OPVEE or naloxone. OPVEE was found to be non-inferior and superior to naloxone in the speed of reversing opioid-induced respiratory depression.
OPVEE shows rapid reversal of opioid effects in study
OPVEE shows rapid reversal of opioid effects in study
Investing.com | Editor Brando Bricchi
Published Mar 11, 2024 18:52
Be the first to comment
OPVEE shows rapid reversal of opioid effects in study
RICHMOND, Va. - Indivior PLC (LSE/Nasdaq: LON:INDV) has announced the results of a pharmacodynamic study indicating that its drug OPVEE® can quickly reverse opioid-induced respiratory depression, a major cause of death in opioid overdoses. The study, comparing intranasal nalmefene (OPVEE) with intranasal naloxone, was published in the Journal of Clinical Pharmacology.
The study met its primary endpoint by showing that OPVEE reversed respiratory depression within five minutes of administration, while naloxone took 20 minutes to achieve a similar effect. Minute ventilation, a measure of breathing, reached approximately 95% of the pre-opioid baseline within five minutes after OPVEE was administered.
In the study, 69 healthy volunteers experienced a reduction in minute ventilation after being administered remifentanil, a synthetic opioid. They were then treated with either OPVEE or naloxone. OPVEE was found to be non-inferior and superior to naloxone in the speed of reversing opioid-induced respiratory depression.
ADVERTISEMENT
Although adverse events were reported in over 90% of subjects following both drugs, these were mostly mild to moderate and were attributed to the remifentanil and experimental conditions rather than the drugs themselves. Common adverse events included headache, nausea, vomiting, and dizziness.
Get The App
Join the millions of people who stay on top of global financial markets with Investing.com.
Download Now
The urgency for rapid-acting opioid reversal agents is underscored by the high number of opioid overdose deaths, which in the United States totaled over 80,000 in the 12 months ending in September 2023, with synthetic opioid
Article from Investing.com (Published Mar 11, 2024 18:52)
https://uk.investing.com/news/stock-market-news/opvee-shows-rapid-reversal-of-opioid-effects-in-study-93CH-3376280
I will take my prediction back from yesterday as £18 quite possibe today with thus game changing news
A bit of profit taking by the Directors, nothing to worry about and certainly no concerning news otherwise it would be tantamount to insider trading which is of course illegal. Of course it's not ideal when Directors sell but they've only top sliced and still have significant holdings so onwards and upwards from here. My target is still £18 in the short term, and hoping it hits that by March end.
Big drop since the Directors/PDMR sells which is frustrating. How low is this going? 😞
No idea, been surfing to see any news, but nothing !!
Has to be a big sell waiting in the wings over the weekend.
It has made a comeback in the last hour…but obviously still down…
Anyone know what caused the -6% drop at the open ?
I would not want this taken over. They’ll steal it at a low price vs. where it can be on its own.
Nice 7% rise on Wall Street today, taking the weekend price up to $23, or £18.17.
SP still well behind the curve based on last results. Broker upgrades to come together with share buy-backs until April & a move to USA. I would also throw in takeover speculation as big pharma circles this relative minnow.
LAST RNS 22 February 2024: Following the above transaction and cancellation of the purchased shares, Indivior has 135,272,708 ordinary shares with voting rights in issue.Â
Today's RNS : Following the above transaction and cancellation of the purchased shares, Indivior has 136,490,175 ordinary shares with voting rights in issue.Â
How on earth has the outstanding company shares total jumped up by 1.22 million shares?
One to send to I.R. because it is not correct.
They have only spent $42 million so far.
Is the company share buy back declared on 17 November 2023 complete? There has been no RNS for the last 2 business days in respect to the same.
Looking for another good day , and brokers updates here
He made an amazing fundamental case for this around £12 last month as he did with Beazley at £5. Both absolutely soared. Well done that man. Probably one of the best investors out there, consistently makes outstanding calls
For a start saving 23pc I am a fan !
List in us is a great move most sharholders already 70pc versus 30pc here
Https://www.ft.com/content/0feaa62e-f574-43dc-adcc-8863861aa606
Looks like US likes INDV, it is up 24% now,excellent
Sadly but inevitably the only way forward for iNDV to reach its full potential and achieve full shareholder value is to make the companies listing primarily in the USA, massive unjustified divide between the two bourses, UK Plc being kept/played artificially low to enable potential US takeovers at ridiculously low levels just look at the likes of BT, VOD LLOY etc etc great businesses but on the wrong bourse imo I for one will be giving it the thumbs up when asked to vote on the switch, lovely rise today which I expected after Tuesdays shenanigans just proves my point
All pharma has endless stream of litigation.
Worst case if multiple never goes up, they can keep buying cheap shares.
Well must admit those numbers far exceeded my expectations…
Was hopeful, but too many times there has been a dampener put on the reports, not this time..
It looks looks like a strong buy until you read note 13 re. legal proceedings. It'll never trade at a decent multiple given the seemingly endless stream of litigation... Nevertheless, a nice trade this morning and good luck to those who hold for the US listing...
Cracking average I'm at 8.18
INDV continues to storm ahead despite increased competition. The SP was far too low so today's price increase is just partial catch-up. The switch to US main listing is a good move & will generate a lot more interest from US based investors. The big questions are how much longer will INDV remain independent before big PHARMA swallows it and at what price? To answer my own questions, not that long & North of £25.